About Karo Bio
Business Model
Company History
1987 - 2000
2001
2002
2003
2004
2005
2006
2007
Board of Directors
Executive Management
Market
Organization
Contact Karo Bio
Corporate Governance
Corporate Citizenship
Glossary
Search
2006
Start Page
»
About Karo Bio
»
Company History
»
2006
Karo Bio completed phase I clinical trials with KB2115 and the first phase II study is ongoing
Karo Bio received a milstone payment from Wyeth for selection of a candidate drug and an additional milestone payment for initiation of phase I clinical studies. The collaboration was extended for an additional year until August 31, 2007
KB5359 was selected as a candidate drug for treatment of dyslipidemia and preclinical development was initiated
The clinical development of KB3305 was delayed due to technical issues with the pharmaceutical formulation
Merck initiated phase I clinical studies in the field of estrogen receptors and women's health with a collaboration compound
Karo Bio outlicensed a class of selective androgen receptor modulators (SARMs) for treatment of osteoporosis to Radius